3Bhatia J. Current option in the management of apnea of prematurity [J]. Clin Pediatr. 2000, 39(6) :327-336.
4Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in apnea of prematurity [J]. Clin Pharmacol Ther, 1997, 61:628-640.
5Erenberg A, Leff R, Wynne B, et al. Results of the first double-blind placebo-controlled study of caffeine citrate for the treatment of apnea of prematurity(AOP) [J]. Pediatr. 1998, 102:756-757.
6Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnea of prematurity [J]. Paediatr Drugs. 2001, 3(1):61-79.
7Poets CF, Darraj S, Bohnhorst B. Effect of doxapram on episodes of apnea, bradycardia and hypoxaemia in preterm infants. Biol Neonate 1999, 76:207-213.
8Sreenan C, Lemke RP, Hudson-Mason A, et al. High-flow nasal cannulae in the management of apnea of prematurity:a comparison with conventional nasal continuous positive airway pressure[J]. Pediatr. 2001, 107(5) :1081-1083.
9Lemyre B, Davis PG, de Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity[J]. Cochrane Database Syst Rev. 2002, (1): CD002272.
10Janvier A,Khairy M,Kokkotis A,et al.Apnea is associated with neurodevelopmental impairment in very low birth weight infants[J].J Perinatol,2004,24(12):763-768.
